ClinicalTrials.Veeva

Menu
H

Hamilton Medical Research Group | Hamilton, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Obeldesivir
Tirzepatide
Ritonavir
BLU-5937
Finerenone
Gefapixant
ATB-346
Bupropion
MK-4482-002
AT-527

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 39 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of ag...

Active, not recruiting
Pneumococcal Infection
Biological: V116
Biological: PPSV23

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegaloviru...

Active, not recruiting
Cytomegalovirus
Biological: mRNA-1647
Other: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling
Weight Gain
Obesity
Drug: Tirzepatide
Drug: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo
Locations recently updated

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Enrolling
Diabetes Mellitus, Type 2
Drug: Retatrutide
Drug: Semaglutide

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their...

Enrolling
Distal Sensory Polyneuropathy
Neuropathic Pain
Drug: Placebo
Drug: LY3848575

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in...

Active, not recruiting
Osteoarthritis, Knee
Biological: PTP-001
Other: Placebo control

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Lilly logo
Pfizer logo
Bayer logo
Boehringer Ingelheim logo
Moderna logo
Gilead Sciences logo
Allergy Therapeutics logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems